Matthew L. Sherman

This profile gathers the share dealings of Matthew L. Sherman across 3 companies, led by Deciphera Pharmaceuticals, Inc., Acceleron Pharma Inc and Pulmatrix, Inc. The record holds 54 filings, for trades running from 3 March 2016 to 11 June 2024.

Both buying and selling appear: 1 purchase, against 28 sales worth €3.4M. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 13 share grants and 10 option exercises. 2024 to date brings no purchases and 2 sales.

The record was last updated on 11 June 2024 with a transaction in Deciphera Pharmaceuticals, Inc. The last insider purchase was made public on 5 April 2018, 3,123 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.